Cholesterol 2% | Lovastatin 2%

Route: Topical application to affected porokeratosis lesions.

• Apply a thin layer to lesion areas twice daily as directed by the prescriber.
• Gently massage into the affected skin until absorbed.
• Topical application bypasses hepatic first-pass metabolism of lovastatin, directing the drug to skin keratinocytes without significant systemic statin exposure.
• Wash hands after application unless treating the hands.

Dosing frequency is typically twice daily; duration of treatment is prescriber-determined based on clinical response. In published case series, near-complete resolution of DSAP lesions occurred within 4–8 weeks in some patients. The prescriber will specify total quantity, frequency, and follow-up interval.

• Lovastatin (topical 2%): Competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway. In porokeratosis, loss-of-function mutations in mevalonate pathway enzymes (MVK, PMVK, MVD, FDPS) lead to accumulation of toxic mevalonate precursors in keratinocytes. Topical lovastatin inhibits the proximal step (HMG-CoA → mevalonate), preventing buildup of these intermediates while bypassing hepatic metabolism so systemic cholesterol synthesis is not significantly affected.
• Cholesterol (topical 2%): Directly replenishes cholesterol—the depleted end-product of the impaired mevalonate pathway—in the stratum corneum and keratinocyte membranes, restoring epidermal barrier lipid matrix, reducing keratinocyte apoptosis susceptibility, and correcting the functional cholesterol deficiency that contributes to the clinical and histological features of porokeratosis.

This dual-mechanism topical therapy for porokeratosis (particularly DSAP and linear porokeratosis) is based on published proof-of-concept case series and small clinical trials demonstrating significant lesion clearance. The rationale is biochemically sound: inhibiting proximal mevalonate pathway enzyme activity with lovastatin while supplementing the deficient end-product (cholesterol) addresses both limbs of the pathogenesis model.

Prescriber monitoring:

• Assess clinical response (lesion size, erythema, scale) at 4- to 8-week intervals.
• Because systemic statin absorption from topical application is minimal, routine liver function or CK monitoring is not typically required, but assess if any systemic symptoms arise.
• Porokeratosis carries a small risk of malignant transformation (squamous cell carcinoma) in long-standing lesions; continued dermatologic surveillance is recommended independently of this therapy.

Contraindications:

• Known hypersensitivity to lovastatin, cholesterol (as a formulation component), or any excipient
• Active skin infection at the application site

Warnings & Precautions:

• Topical lovastatin at 2% is not expected to produce significant systemic statin effects; however, use caution in patients who have demonstrated hypersensitivity to systemic statins.
• Monitor for local skin irritation, which may require dose reduction or temporary discontinuation.
• Porokeratosis lesions have a small risk of malignant transformation; any rapidly changing lesion should be biopsied.

Drug Interactions:

• Systemic statin interactions are not expected from topical application; however, concomitant systemic statin therapy adds to total lovastatin exposure.

Common Side Effects: Local skin irritation, erythema, and pruritus at the application site; these effects are generally mild and transient. No systemic statin-related side effects (myopathy, hepatotoxicity) are anticipated from topical low-concentration use.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from excessive heat and light. Keep container tightly sealed. Do not freeze. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

What is porokeratosis and why is this combination used?

Porokeratosis is a chronic skin condition characterized by abnormal keratinocyte clones with defects in the mevalonate (cholesterol biosynthesis) pathway. This results in cholesterol deficiency and accumulation of toxic pathway intermediates in skin cells. Topical lovastatin prevents intermediate buildup while topical cholesterol replenishes the deficient end-product—a pathogenesis-directed dual approach.

Why is a statin applied to the skin rather than taken orally?

Topical application delivers lovastatin directly to keratinocytes in the skin, bypassing hepatic first-pass metabolism. This allows the drug to act specifically at the site of pathology (skin) with minimal systemic statin exposure, avoiding systemic side effects such as myopathy or elevated liver enzymes.

How long before I see improvement?

Published case series report significant improvement within 4–8 weeks of twice-daily application. Response varies by lesion type and thickness; your prescriber will assess treatment response at follow-up visits.

Is this product FDA-approved?

No FDA-approved combination topical lovastatin/cholesterol product exists for porokeratosis. This is a 503A compounded preparation from Genesis Compounding based on published evidence and prescriber judgment. The individual components (lovastatin, cholesterol) have established pharmacology.

Does this treat all types of porokeratosis equally?

Clinical series suggest DSAP (disseminated superficial actinic porokeratosis) responds well; thicker or atrophic plaques (as in linear porokeratosis) may have partial responses. Your prescriber will assess the type and extent of your condition to inform expectations.